Mortality and Medicare Disability Eligibility Status of HCV Population in the US
The study examines excess mortality burden of HCV-diagnosed individuals, Medicare eligibility due to disability, comparison of medical costs for disabled and non-disabled HCV beneficiaries, and 2012 costs for deceased HCV-diagnosed beneficiaries.
Download Presentation
Please find below an Image/Link to download the presentation.
The content on the website is provided AS IS for your information and personal use only. It may not be sold, licensed, or shared on other websites without obtaining consent from the author.If you encounter any issues during the download, it is possible that the publisher has removed the file from their server.
You are allowed to download the files provided on this website for personal or commercial use, subject to the condition that they are used lawfully. All files are the property of their respective owners.
The content on the website is provided AS IS for your information and personal use only. It may not be sold, licensed, or shared on other websites without obtaining consent from the author.
E N D
Presentation Transcript
The Increased Mortality and the Medicare Disability Eligibility Status of the HCV Population in the US Gabriela Dieguez1, Bruce Pyenson1, Steven E Marx2, Yuri Sanchez Gonzalez2 1 Milliman Inc. 2 AbbVie Inc. November 13, 2016 AASLD
Disclosures and Conflicts of Interest Gabriela Dieguez and Bruce Pyenson are employed by Milliman, Inc., which received consulting fees from AbbVie for conducting research and analysis Steven Marx and Yuri Sanchez Gonzalez are AbbVie employees and own AbbVie stock The design, analysis, and financial support of this study were provided by AbbVie. AbbVie participated in the interpretation of data, review, and approval of the study 2 The Increased Mortality and the Medicare Disability Eligibility Status of the HCV Population in the US November 13, 2016 AASLD
Goals Assess excess mortality burden for HCV-diagnosed beneficiaries Explain how HCV-diagnosed people qualify for Medicare before age 65 through disability Compare medical costs for disabled and non-disabled Medicare HCV beneficiaries Identify 2012 costs for HCV-diagnosed beneficiaries who died Source: http://redpacientes.com/wall/9833 3 The Increased Mortality and the Medicare Disability Eligibility Status of the HCV Population in the US November 13, 2016 AASLD
Background Medicare covers people > age 65 ( aged ) and some people <65 who are disabled Are people with HCV more likely to enter Medicare before age 65? Are people with HCV more likely to die? What are the costs associated with HCV-related deaths? 4 The Increased Mortality and the Medicare Disability Eligibility Status of the HCV Population in the US November 13, 2016 AASLD
Methods to Assess the Burden of HCV to Medicare Compare rates of Medicare eligibility for HCV- diagnosed and general US population <65 Compare mortality for HCV- diagnosed to standard mortality rates Identify HCV status and liver disease stage Tabulate Medicare costs for HCV- diagnosed 5 The Increased Mortality and the Medicare Disability Eligibility Status of the HCV Population in the US November 13, 2016 AASLD
Data Sources 2012 Medicare 5% database (medical claims and demographics) -Includes diagnoses, reason for eligibility, death indicator Census data (National Health and Nutrition Examination Survey) 2010 Period Life Table (US Census Bureau) 6 The Increased Mortality and the Medicare Disability Eligibility Status of the HCV Population in the US November 13, 2016 AASLD
Results: Mortality and Medicare Disability Rates in the US (1) HCV (2) US (3) = (1) / (2) HCV to US Population HCV Stage Population Annual Mortality Rates 0.0660 0.0600 0.0973 0.1861 0.0692 0.0736 Population* Medicare beneficiaries with HCV have almost 5 times the annual mortality of non- diagnosed beneficiaries Newly Diagnosed Non-Cirrhotic Cirrhotic ESLD Transplant All HCV *Age/gender adjusted to the HCV cohort 0.0205 0.0146 0.0151 0.0133 0.0125 0.0154 3.2 4.1 6.4 14.0 5.5 4.8 (1) HCV (2) US (3) = (1) / (2) HCV to US Population HCV Stage No difference in rate of Medicare-eligibility through disabilityfor HCV diagnosed and non-diagnosed Population Medicare Disability** 0.0102 Population All HCV ** Medicare disability defined as eligibility to Medicare benefits through disability 1.0 0.0102 7 The Increased Mortality and the Medicare Disability Eligibility Status of the HCV Population in the US November 13, 2016 AASLD
Results: Medicare Costs for HCV Disabled On average, HCV-diagnosed Medicare disabled are 19 years younger than Medicare aged1beneficiaries diagnosed with HCV $35,000 Average Annual Medical Cost (2012) $30,000 $25,000 Average Age: 54 Average Age: 73 $20,000 $30,700 $15,000 $29,800 However, annual medical costs for Medicare disabled and aged1 with HCV are similar. $10,000 $5,000 $0 HCV Disabled HCG Aged HCV 1Medicare Aged defined as beneficiaries first eligible for Medicare by attaining age 65. 8 The Increased Mortality and the Medicare Disability Eligibility Status of the HCV Population in the US November 13, 2016 AASLD
Results: Average Medicare Costs in the Last Year of Life Average medical expenses in last 12 months of life: $107,838, over 3 times the annualized cost for all HCV patients (2012) $30,000 Average Monthly Cost Per Patient (2012) $25,000 $20,000 $15,000 $25,568 Average monthly cost for all HCV patients with Medicare $10,000 $16,434 $11,479 $10,666 $5,000 $8,027 $6,211 $6,110 $5,560 $4,975 $4,929 $4,147 $2,5 29 $3,732 $2,529 $0 0 1 2 3 4 5 6 7 8 9 10 11 All HCV Patients Months Before Death Notes: Assuming patients die, on average, mid-month 9 The Increased Mortality and the Medicare Disability Eligibility Status of the HCV Population in the US November 13, 2016 AASLD
Study Limitations HCV status and liver disease stages were identified through diagnosis codes in administrative claims databases and are susceptible to provider coding practices. This study excludes undiagnosed individuals infected with HCV and those that are missing an HCV diagnosis code in their claims data. Medical costs, mortality rates, and Medicare disability status may not be attributable entirely to the HCV diagnosis; we did not attempt to measure the impact of comorbidities associated with HCV on these variables. Medicare eligibility through disability drops sharply as individuals reach age 65. Patients with HCV that may have qualified through disability but instead waited until age 65 to enroll in Medicare are identified as aged in this study. 10 The Increased Mortality and the Medicare Disability Eligibility Status of the HCV Population in the US November 13, 2016 AASLD
Conclusions Medicare-covered HCV patients are associated with higher mortality rates than people of the same age and gender, but not with higher Medicare disability rates Medicare disabled patients with HCV are 19 younger than Medicare aged (non-disabled) patients with HCV, but had similar average medical costs (about $30,000 per year) Average medical costs for Medicare-covered HCV patients that died in 2012 are over $100,000 in the last year of life, and cost peaks in the last month of life at over $25,000 11 The Increased Mortality and the Medicare Disability Eligibility Status of the HCV Population in the US November 13, 2016 AASLD
